TRIB Stock Overview
Acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Trinity Biotech plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.04 |
| 52 Week High | US$5.25 |
| 52 Week Low | US$1.49 |
| Beta | 1.31 |
| 11 Month Change | -2.86% |
| 3 Month Change | 5.70% |
| 1 Year Change | -52.71% |
| 33 Year Change | -83.61% |
| 5 Year Change | -83.00% |
| Change since IPO | -97.45% |
Recent News & Updates
Recent updates
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More
Jun 11
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%
Mar 02Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry
Dec 18A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)
Sep 12Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?
Aug 08Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price
Jun 09Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)
Apr 23This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts
Apr 23Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 01Trinity Biotech appoints former GE executive Aris Kekedjian as CEO
Oct 03At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?
Sep 01Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
Jun 30Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)
Jun 14Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 23Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?
Feb 25Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability
Feb 02
A Treatise On Trinity Biotech
Jan 13Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?
Jan 05What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?
Dec 10Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt
Nov 19Trinity Biotech EPS beats by $0.22, beats on revenue
Nov 17Shareholder Returns
| TRIB | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.2% | -0.5% | 1.8% |
| 1Y | -52.7% | -0.4% | 24.2% |
Return vs Industry: TRIB underperformed the US Medical Equipment industry which returned -0.4% over the past year.
Return vs Market: TRIB underperformed the US Market which returned 24% over the past year.
Price Volatility
| TRIB volatility | |
|---|---|
| TRIB Average Weekly Movement | 14.7% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TRIB's share price has been volatile over the past 3 months.
Volatility Over Time: TRIB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 380 | John Gillard | www.trinitybiotech.com |
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
Trinity Biotech plc Fundamentals Summary
| TRIB fundamental statistics | |
|---|---|
| Market cap | US$19.31m |
| Earnings (TTM) | -US$33.88m |
| Revenue (TTM) | US$56.71m |
0.3x
P/S Ratio-0.6x
P/E RatioIs TRIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRIB income statement (TTM) | |
|---|---|
| Revenue | US$56.71m |
| Cost of Revenue | US$37.31m |
| Gross Profit | US$19.40m |
| Other Expenses | US$53.28m |
| Earnings | -US$33.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.58 |
| Gross Margin | 34.21% |
| Net Profit Margin | -59.75% |
| Debt/Equity Ratio | -322.1% |
How did TRIB perform over the long term?
See historical performance and comparison